MAI-001 by Nanjing Minova Pharmaceutical Technology for Depression: Likelihood of Approval

MAI-001 is under clinical development by Nanjing Minova Pharmaceutical Technology and currently in Phase I for Depression.

More than 70 babies have been born from uterus transplants: ‘It’s a complete new world’

The first modern attempt at transferring a uterus from one human to another occurred at the turn of the millennium. But surgeons had to remove

August 16, 2024

Synergistic winter flounder antimicrobial peptides unveil new path to enhanced bactericidal therapy

The synergistic action of six winter flounder (WF) antimicrobial peptides (AMPs) against bacterial pathogens.

August 14, 2023

Researchers investigate the feasibility of new home-administered treatment for binge eating disorder

Researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London have investigated the feasibility of a new home-administered treatment for binge

June 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.